Blockchain Registration Transaction Record

Helus Pharma CEO to Speak at Jefferies Global Healthcare Conference

Helus Pharma interim CEO Eric So to speak at Jefferies Global Healthcare Conference. Company developing novel serotonergic agonists for depression and anxiety. HLP003 in Phase 3 with Breakthrough Therapy Designation.

This news matters because Helus Pharma is advancing novel treatments for major depressive disorder and generalized anxiety disorder, conditions affecting millions globally. The company's Breakthrough Therapy Designation for HLP003 signals potential for faster regulatory review and market access, which could provide new options for patients with treatment-resistant depression. The Jefferies conference fireside chat offers investors and stakeholders insight into the company's strategic direction and clinical progress.